Rigel Pharmaceuticals (RIGL) Operating Income (2010 - 2026)

Rigel Pharmaceuticals' Operating Income history runs 17 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• In Q1 2026, Operating Income fell 6.95% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $124.6 million (up 183.58% YoY), while the FY2025 annual figure was $125.5 million, up 418.63% from the prior year.
• Operating Income for Q1 2026 stood at $11.9 million, down from $23.2 million in the prior quarter.
• The five-year high for Operating Income was $61.1 million in Q2 2025, with the low at -$26.3 million in Q1 2022.
• The 5-year median for Operating Income is $2.0 million (2023), against an average of $5.0 million.
• The sharpest annual moves came in 2022 and 2025: Operating Income tumbled 162.89% in 2022, then soared 13569.57% in 2025.
• Rigel Pharmaceuticals' Operating Income stood at $2.1 million in 2022, then decreased by 5.44% to $2.0 million in 2023, then jumped by 747.15% to $16.7 million in 2024, then jumped by 39.12% to $23.2 million in 2025, then plunged by 48.71% to $11.9 million in 2026.
• Business Quant data shows RIGL's Operating Income at $11.9 million in Q1 2026, $23.2 million in Q4 2025, and $28.4 million in Q3 2025.